Clinlogix offers clinical research services for novel and emerging technologies to the customers in the medical device industry
Clinlogix supported over 500 trials across 3,500 sites globally. (Credit: Adam Radosavljevic/Pixabay)
North American Science Associates (NAMSA) has acquired Philadelphia-based global medical device-focused contract research organisation (CRO) Clinlogix for an undisclosed sum.
Established in 1999, Clinlogix offers clinical research services for novel and emerging technologies to customers in the medical device industry.
The firm’s suite of clinical research services supports the regulatory and clinical development pathway of medical devices, biotechnologies and pharmaceuticals from bench to bedside.
The acquisition of Clinlogix follows the announcements made by NAMSA earlier this year to buy Syntactx and American Preclinical Services (APS).
Minneapolis-based APS is a full service preclinical CRO, while Syntactx is a New York-based CRO that was founded in 2010.
NAMSA president and CEO Dr Christophe Berthoux said: “Today is an exciting day as the Clinlogix Team joins NAMSA. We are thrilled to partner with an organization that is equally committed to client success, evidenced through Clinlogix’s consistent delivery of reliable clinical outcomes to global device sponsors.”
Clinlogix claims to have global expertise in the areas of cardiovascular, neurology, nephrology, urology, oncology and venous/wound care clinical research.
With regional office locations in the US, Germany, Colombia and Japan, the company supported over 500 trials across 3,500 sites globally.
Clinlogix CEO JeanMarie Markham said: “Clinlogix is extremely pleased to join NAMSA, an organization that shares the same patient-centric, client-focused philosophy as we do. For over 20 years, our focus has been on providing a global ‘innovation pathway’ for Clients developing novel and emerging technologies.”
NAMSA also offers quality, reimbursement, clinical research and regulatory solutions, in addition to testing services to sponsors.
It currently serves sponsors across 17 locations in Asia-Pacific, Europe, Latin America and North America.
The CRO’s end-to-end development services provided by NAMSA will help sponsors to meet the varying global regulatory requirements, including recently expanded criteria for medical device and in vitro diagnostic research and conduct.